Flagship Harbor Advisors LLC Has $374,000 Holdings in Novartis AG (NYSE:NVS)

Flagship Harbor Advisors LLC lifted its holdings in shares of Novartis AG (NYSE:NVS) by 7.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,842 shares of the company’s stock after acquiring an additional 262 shares during the quarter. Flagship Harbor Advisors LLC’s holdings in Novartis were worth $374,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in NVS. Fisher Asset Management LLC boosted its position in Novartis by 15.7% during the third quarter. Fisher Asset Management LLC now owns 1,706,009 shares of the company’s stock worth $196,225,000 after purchasing an additional 231,851 shares during the period. FMR LLC lifted its stake in shares of Novartis by 5.5% during the 3rd quarter. FMR LLC now owns 1,353,412 shares of the company’s stock worth $155,669,000 after buying an additional 70,314 shares during the last quarter. Natixis Advisors LLC boosted its holdings in shares of Novartis by 2.9% during the 3rd quarter. Natixis Advisors LLC now owns 938,844 shares of the company’s stock worth $107,986,000 after buying an additional 26,317 shares during the period. Bank of Montreal Can grew its stake in Novartis by 18.7% in the 3rd quarter. Bank of Montreal Can now owns 780,980 shares of the company’s stock valued at $90,289,000 after buying an additional 123,077 shares during the last quarter. Finally, Creative Planning raised its holdings in Novartis by 4.1% in the 3rd quarter. Creative Planning now owns 344,951 shares of the company’s stock valued at $39,676,000 after acquiring an additional 13,486 shares during the period. 13.12% of the stock is owned by institutional investors and hedge funds.

Novartis Trading Down 1.5 %

Shares of NYSE:NVS opened at $101.85 on Wednesday. The business’s 50 day simple moving average is $100.10 and its 200 day simple moving average is $108.64. The company has a market capitalization of $208.19 billion, a P/E ratio of 11.83, a P/E/G ratio of 1.42 and a beta of 0.57. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.11 and a quick ratio of 0.90. Novartis AG has a 1 year low of $92.35 and a 1 year high of $120.92.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The firm had revenue of $12.82 billion for the quarter, compared to the consensus estimate of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same period in the prior year, the company posted $1.74 earnings per share. On average, research analysts anticipate that Novartis AG will post 7.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on NVS shares. BMO Capital Markets boosted their price objective on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a report on Wednesday, October 30th. Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. Finally, HSBC cut Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Two analysts have rated the stock with a sell rating and six have given a hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.